Literature DB >> 29636403

New interventions to treat chronic thromboembolic pulmonary hypertension.

David Jenkins.   

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) can be defined as a type of precapillary pulmonary hypertension (PH) resulting from incomplete resolution of pulmonary embolism. Symptoms are exertional breathlessness and most patients come to a cardiologist's attention with a dilated right heart on echocardiography. Patients with suspected CTEPH should be referred for evaluation to a PH specialist centre to confirm the diagnosis. There are now three treatment options available, dependent on the anatomical level of the obstruction: pulmonary endarterectomy surgery, balloon pulmonary angioplasty and pulmonary arterial hypertension (PAH)-targeted drugs. All reduce pulmonary artery pressure and vascular resistance. Current guidelines recommend surgery as the definitive treatment in technically operable patients. The operation involves deep hypothermic circulatory arrest, but the in-hospital mortality is <5% and the 3-year survival is 90%. Large case series have demonstrated dramatic improvement in haemodynamic parameters with significant symptomatic and prognostic benefits. Balloon pulmonary angioplasty is the newest treatment that has been refined by Japanese cardiologists over the last 5 years. This technique is designed to target more distal subsegmental lesions in inoperable patients and in experienced centres has been shown to deliver equivalent haemodynamic improvement to surgery with low complication rates, but longer term outcome is still under evaluation. A recent randomised controlled trial has demonstrated a reduction in vascular resistance and increase in walk test distance with the PAH-targeted drug Riociguat in patients with inoperable CTEPH, and this drug is now licensed for these patients. It is likely that some patients will benefit from combinations of treatments. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  pulmonary vascular disease; thromboembolic pulmonary vascular disease

Mesh:

Year:  2018        PMID: 29636403     DOI: 10.1136/heartjnl-2017-312110

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  4 in total

Review 1.  Chronic thromboembolic pulmonary hypertension: a review.

Authors:  Cheryl Zhiya Chong; Edgar Lik Wui Tay; Ching Hui Sia; Kian Keong Poh
Journal:  Singapore Med J       Date:  2021-07       Impact factor: 1.858

2.  The long-term survival in patients with chronic thromboembolic pulmonary hypertension: experience from a single center in China.

Authors:  Song Hu; Jiang-Shan Tan; Sheng Liu; Ting-Ting Guo; Wu Song; Fu-Hua Peng; Yan Wu; Xin Gao; Lu Hua
Journal:  J Thromb Thrombolysis       Date:  2021-10-27       Impact factor: 2.300

3.  Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Initial Single-Center Experience.

Authors:  Vidhu Anand; Robert P Frantz; Hilary DuBrock; Garvan C Kane; Michael Krowka; Ryoji Yanagisawa; Gurpreet S Sandhu
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2019-08-23

4.  Preoperative platelet count, preoperative hemoglobin concentration and deep hypothermic circulatory arrest duration are risk factors for acute kidney injury after pulmonary endarterectomy: a retrospective cohort study.

Authors:  Congya Zhang; Guyan Wang; Hui Zhou; Guiyu Lei; Lijing Yang; Zhongrong Fang; Sheng Shi; Jun Li; Zhiyan Han; Yunhu Song; Sheng Liu
Journal:  J Cardiothorac Surg       Date:  2019-12-30       Impact factor: 1.637

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.